Transplantation outcome in allogeneic PBSCT patients according to a new chronic GVHD grading system, including extensive skin involvement, thrombocytopenia, and progressive-type onset

Bone Marrow Transplantation

Volumn 34, Issue 1, 2004, Pages 63-68

  Sohn, S K ^a   Kim, D H ^a   Kim, J G ^a   Lee, N Y ^a   Suh, J S ^a   Lee, K S ^a   Lee, K B ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Allogeneic; Chronic GVHD; PBSCT

Indexed keywords

ANTIBIOTIC AGENT; ARTIFICIAL TEAR; BUSULFAN; CIPOL N; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; LEUCOGEN; LEUKOKINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PSORALEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STEROID; SUNSCREEN; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; LOTION; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROBABILITY; PUVA; SKIN DISEASE; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 3543082701     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704533     Document Type: Article

References (17)

1. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
2. Akpek G, Azhurak ML, Piantadosi S et al. Development of a prognostic model for grading chronic graft-versus-host disease. Blood 2001; 97: 1219-1226.
3. Lee SJ, Klein JP, Barrett AJ et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
4. Sohn SK, Kim JG, Seo KW et al. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002; 30: 81-86.
5. Sohn SK, Kim JG, Chae YS et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003; 18: 10-15.
6. Przepiorka D, Weisdorf D, Martin P et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
7. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds) Bone Marrow Transplantation. Blackwell Scientific: Oxford, 1994; pp 339-362.
8. Akpek G, Lee SJ, Flowers ME et al. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood 2003; 102: 802-809.
9. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
10. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease. N Engl J Med 1981; 304: 1529-1533.
11. Gratwohl A, Brand R, Apperley J et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (CLWP-EBMT). Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877-3886.
12. Przepiorka D, Anderlini P, Saliba R et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-16700.
13. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after HLA-identical sibling transplantation. Blood 2001; 98: 3221-3227.
14. Grigg AP, Szer J, Beresford J et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999; 107: 409-418.
15. Sohn SK, Kim JG, Kim DH et al. Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 31: 967-972.
16. Sohn SK, Jung JT, Kim DH et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.
17. Brunet S, Urbano-Ispizua A, Ojeda E et al. Spanish Group of Allogeneic-PBT, Spain. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114: 544-550.